Following therapy, the survival analysis highlighted the significantly higher risk for short-term relapse and the declined survival of the chB-ALL patients with GAS5 overexpression in BM blasts at diagnosis. The gene discussed is GAS5; the disease is acute lymphoblastic leukemia.